{"nctId":"NCT00825305","briefTitle":"Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)","startDateStruct":{"date":"2008-11"},"conditions":["Rabies"],"count":825,"armGroups":[{"label":"Zagreb (2-1-1)","type":"EXPERIMENTAL","interventionNames":["Biological: Abbreviated Zagreb 2-1-1 schedule"]},{"label":"Essen (1-1-1-1-1)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Standard Essen 1-1-1-1-1 schedule"]}],"interventions":[{"name":"Abbreviated Zagreb 2-1-1 schedule","otherNames":["PCEC Rabies vaccine for human use"]},{"name":"Standard Essen 1-1-1-1-1 schedule","otherNames":["PCEC Rabies vaccine for human use"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects 18-50 years of age who:\n* are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator;\n* volunteer for the simulated post-exposure vaccination courses and blood draws;\n* have given a written informed consent; informed consent must be obtained for all the subjects before enrolment in the study;\n* are available for all the visits scheduled in the study.\n\nExclusion Criteria:\n\n* Subjects with the below criteria were excluded:\n* pregnancy or unwillingness to practice acceptable contraception during participation in the study;\n* a history of rabies immunization;\n* a significant acute or chronic infectious disease that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment;\n* fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrolment;\n* treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrolment;\n* administration of any vaccine within the past 14 days before enrolment;\n* known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;\n* history of allergy to egg protein;\n* known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component;\n* treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months;\n* mental condition rendering the subject unable to understand the nature, scope and consequences of the study;\n* participation in any other investigational trial within the past 3 months before enrolment;\n* planned surgery during the study period;\n* intention to leave the area of the study site before the end of study period;\n* any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rabies Virus Neutralizing Antibody Concentrations on Day 14.","description":"Rabies virus neutralizing antibody concentrations of the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Rabies Virus Neutralizing Antibody Concentrations on Day 7 and Day 42.","description":"Rabies virus neutralizing antibody concentrations the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.23","spread":null},{"groupId":"OG001","value":"-3.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.25","spread":null},{"groupId":"OG001","value":"4.32","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Reported a Local or Systemic Reaction After Any Vaccination","description":"Specified local and systemic reactions were solicited for 7 days after each vaccination. Number of participants were calculated who reported a local or systemic reaction after any of the vaccinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"483","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"475","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants With Seroconversion (Rabies Virus Neutralizing Antibody Concentrations Equal and Above 0.5 IU/ml) on Days 7, 14 and 42.","description":"Percentages of participants with seroconversion (defined as rabies virus neutralizing antibody concentrations equal and above 0.5 IU/ml) on days 7, 14 and 42.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.14","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":549},"commonTop":["Upper respiratory tract infection"]}}}